Cargando…
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598200/ https://www.ncbi.nlm.nih.gov/pubmed/26457056 http://dx.doi.org/10.2147/DMSO.S54953 |
_version_ | 1782394051542122496 |
---|---|
author | Thuillier, Philippe Alavi, Zarrin Kerlan, Véronique |
author_facet | Thuillier, Philippe Alavi, Zarrin Kerlan, Véronique |
author_sort | Thuillier, Philippe |
collection | PubMed |
description | Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy. |
format | Online Article Text |
id | pubmed-4598200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45982002015-10-09 Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes Thuillier, Philippe Alavi, Zarrin Kerlan, Véronique Diabetes Metab Syndr Obes Review Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy. Dove Medical Press 2015-10-01 /pmc/articles/PMC4598200/ /pubmed/26457056 http://dx.doi.org/10.2147/DMSO.S54953 Text en © 2015 Thuillier et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Thuillier, Philippe Alavi, Zarrin Kerlan, Véronique Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
title | Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
title_full | Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
title_fullStr | Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
title_full_unstemmed | Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
title_short | Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
title_sort | long-term safety and efficacy of insulin degludec in the management of type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598200/ https://www.ncbi.nlm.nih.gov/pubmed/26457056 http://dx.doi.org/10.2147/DMSO.S54953 |
work_keys_str_mv | AT thuillierphilippe longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes AT alavizarrin longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes AT kerlanveronique longtermsafetyandefficacyofinsulindegludecinthemanagementoftype2diabetes |